Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Core Viewpoint - Oncolytics Biotech Inc. has decided to wind down the GOBLET gastrointestinal study to concentrate on the registration path for its investigational drug pelareorep in the U.S. for specific cancer indications [2][3]. Group 1: Study Conclusion and Focus Shift - The company has concluded enrollment in the GOBLET study, having gathered sufficient clinical and translational data to inform its next development phase [2]. - Oncolytics will now focus its resources on registrational studies for squamous cell anal cancer (SCAC) and metastatic colorectal cancer (CRC) [2][3]. - The promising efficacy signal observed in GOBLET Cohort 4 has defined a clear path for regulatory approval in second-line and later SCAC, where current therapies provide limited benefits [3]. Group 2: Regulatory Plans - Oncolytics plans to meet with the U.S. Food and Drug Administration (FDA) in mid-April to align on the design of a single-arm SCAC registrational study [4]. - The company believes that a clinical trial involving fewer than 100 subjects will be sufficient to secure FDA approval for this rare cancer indication [4]. Group 3: Enrollment and Data Analysis - The company has decided to stop further enrollment in GOBLET Cohort 5 for metastatic pancreatic ductal adenocarcinoma (PDAC) at approximately 20 patients per arm, believing the existing data is adequate to inform future strategies [5]. - Current enrollment in GOBLET Cohort 5 will allow for analysis of therapy responses, including overall survival, and the company will continue to monitor these patients [6]. Group 4: Insights from GOBLET Study - The GOBLET study has provided valuable insights into the efficacy and safety of pelareorep in gastrointestinal cancers, supporting the company's platform approach in this area [7]. - The study is a phase 1/2 multiple indication study conducted at 17 centers in Germany, focusing on various treatment combinations for advanced or metastatic gastrointestinal tumors [7][10]. Group 5: About Oncolytics Biotech Inc. - Oncolytics is a clinical-stage biotechnology company developing pelareorep, which has shown encouraging results in multiple cancer studies and is designed to activate immune responses against tumors [10][11]. - The company is actively pursuing strategic partnerships to accelerate development and maximize commercial impact [11].